BACKGROUND: Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas. METHODS: Two arms were opened, each using a Simon two-stage design. Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma. Arm B accrued patients with other types of soft tissue sarcomas. Patients were not allowed to have received previous chemotherapy for metastatic disease. The initial dose of bortezomib was a 1.5 mg/m2 intravenous push twice weekly followed by a rest week. The dose was escalated to 1.7 mg/m2 if patients tolerated Cycle 1 well. The dose escalation was eliminated due to toxicity observed in the first six patients. RESULTS: Painful neuropathy, myalgias, and asthenia were the most significant observed toxicities. The most frequent toxicities included fatigue, diarrhea, constipation, and nausea. Pharmacodynamic data from 18 patients with complete data collection did not show consistent differences between patients with or without Grade 2 or Grade 3 neuropathy (toxicity graded according the National Cancer Institute Common Toxicity Criteria). Arm A had low accrual and was closed. One confirmed partial response among 21 evaluable patients was observed on Arm B in a patient with leiomyosarcoma. Due to the inactivity of this agent, the study was closed after the first stage of accrual. CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent. If studied further in sarcomas, bortezomib should be investigated in combination with agents with demonstrated preclinical synergy. Copyright 2005 American Cancer Society.
BACKGROUND: Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas. METHODS: Two arms were opened, each using a Simon two-stage design. Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma. Arm B accrued patients with other types of soft tissue sarcomas. Patients were not allowed to have received previous chemotherapy for metastatic disease. The initial dose of bortezomib was a 1.5 mg/m2 intravenous push twice weekly followed by a rest week. The dose was escalated to 1.7 mg/m2 if patients tolerated Cycle 1 well. The dose escalation was eliminated due to toxicity observed in the first six patients. RESULTS:Painful neuropathy, myalgias, and asthenia were the most significant observed toxicities. The most frequent toxicities included fatigue, diarrhea, constipation, and nausea. Pharmacodynamic data from 18 patients with complete data collection did not show consistent differences between patients with or without Grade 2 or Grade 3 neuropathy (toxicity graded according the National Cancer Institute Common Toxicity Criteria). Arm A had low accrual and was closed. One confirmed partial response among 21 evaluable patients was observed on Arm B in a patient with leiomyosarcoma. Due to the inactivity of this agent, the study was closed after the first stage of accrual. CONCLUSIONS:Bortezomib has minimal activity in soft tissue sarcoma as a single agent. If studied further in sarcomas, bortezomib should be investigated in combination with agents with demonstrated preclinical synergy. Copyright 2005 American Cancer Society.
Authors: Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore Journal: Mol Oncol Date: 2013-12-15 Impact factor: 6.603
Authors: William R Schelman; Anne M Traynor; Kyle D Holen; Jill M Kolesar; Steven Attia; Tien Hoang; Jens Eickhoff; Zhisheng Jiang; Dona Alberti; Rebecca Marnocha; Joel M Reid; Matthew M Ames; Renee M McGovern; Igor Espinoza-Delgado; John J Wright; George Wilding; Howard H Bailey Journal: Invest New Drugs Date: 2013-10-10 Impact factor: 3.850
Authors: Jason A Somarelli; Amy M Boddy; Heather L Gardner; Suzanne Bartholf DeWitt; Joanne Tuohy; Kate Megquier; Maya U Sheth; Shiaowen David Hsu; Jeffrey L Thorne; Cheryl A London; William C Eward Journal: Mol Biol Evol Date: 2020-01-01 Impact factor: 16.240
Authors: Christopher Lieu; Laura Chow; A Scott Pierson; S Gail Eckhardt; Cindy L O'Bryant; Mark Morrow; Zung Vu Tran; John J Wright; Lia Gore Journal: Invest New Drugs Date: 2008-07-11 Impact factor: 3.850
Authors: Neerav Shukla; Romel Somwar; Roger S Smith; Sri Ambati; Stanley Munoz; Melinda Merchant; Padraig D'Arcy; Xin Wang; Rachel Kobos; Christophe Antczak; Bhavneet Bhinder; David Shum; Constantin Radu; Guangbin Yang; Barry S Taylor; Charlotte K Y Ng; Britta Weigelt; Inna Khodos; Elisa de Stanchina; Jorge S Reis-Filho; Ouathek Ouerfelli; Stig Linder; Hakim Djaballah; Marc Ladanyi Journal: Cancer Res Date: 2016-06-02 Impact factor: 12.701